BRU · UCB.BR
UCB S.A.
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
Loading market information…
BRU · SEQUA.BR · EUR
Stock price, earnings
Quote as of Apr 28, 2026, 03:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Sequana Medical N.V.’s quoted price sits in the lower half of its reported 52-week range, 62.24% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sequana Medical N.V.’s next earnings report is currently expected on Mar 26, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sequana Medical N.V.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sequana Medical N.V. is a medical technology company that has reached the commercial stage, dedicated to creating innovative solutions for managing excessive fluid accumulation linked to liver conditions, malignant ascites, and heart failure. The company's key offerings include the alfapump® system, an implanted device specifically designed to treat severe and resistant liver ascites as well as malignant ascites (fluid buildup caused by cancer). Additionally, it provides Direct Sodium Removal (DSR) technology to address ongoing fluid congestion in patients with heart failure. This DSR technology is integrated into the alfapump® DSR system, a fully implantable solution for direct sodium removal therapy in heart failure patients experiencing fluid overload. Established in 2006 and headquartered in Ghent, Belgium, Sequana Medical operates across Belgium, Germany, France, Switzerland, and other international regions.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:04 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -€0.57 |
| €328.00K |
| Q2 2023 | Sep 14, 2023 | -€0.65 | €384.00K |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
€804.40+€7.80 (+0.98%)
argenx SE’s quoted price sits in the upper half of its reported 52-week range, 13.04% below the high.
€42.89+€0.30 (+0.7%)
Siemens Healthineers AG’s quoted price sits in the upper half of its reported 52-week range, 13.7% below the high.
€227.60+€6.80 (+3.08%)
Financière de Tubize S.A.’s quoted price sits in the upper half of its reported 52-week range, 9.14% below the high.
€28.90+€0.34 (+1.19%)
Lakefront Biotherapeutics’s quoted price sits in the upper half of its reported 52-week range, 5.92% below the high.
€16.46+€0.12 (+0.73%)
Ion Beam Applications S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.32% below the high.
$3.17+$0.65 (+25.6%)
Pulmonx Corporation’s quoted price sits in the upper half of its reported 52-week range, 2.62% below the high.
$1.28$0.00 (0.0%)
Sonendo, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.63% below the high.
